- Home
- TACH vs KMDA Comparison
TACH vs KMDA Comparison
Compare TACH & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACH
- KMDA
- Stock Information
- Founded
- TACH 2024
- KMDA 1990
- Country
- TACH United States
- KMDA Israel
- Employees
- TACH N/A
- KMDA N/A
- Industry
- TACH
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- TACH
- KMDA Health Care
- Exchange
- TACH Nasdaq
- KMDA Nasdaq
- Market Cap
- TACH 345.7M
- KMDA 399.7M
- IPO Year
- TACH 2025
- KMDA N/A
- Fundamental
- Price
- TACH $10.10
- KMDA $7.20
- Analyst Decision
- TACH
- KMDA Strong Buy
- Analyst Count
- TACH 0
- KMDA 3
- Target Price
- TACH N/A
- KMDA $14.67
- AVG Volume (30 Days)
- TACH 32.9K
- KMDA 71.8K
- Earning Date
- TACH 01-01-0001
- KMDA 08-13-2025
- Dividend Yield
- TACH N/A
- KMDA 2.77%
- EPS Growth
- TACH N/A
- KMDA 31.21
- EPS
- TACH N/A
- KMDA 0.28
- Revenue
- TACH N/A
- KMDA $167,235,000.00
- Revenue This Year
- TACH N/A
- KMDA $14.51
- Revenue Next Year
- TACH N/A
- KMDA $9.31
- P/E Ratio
- TACH N/A
- KMDA $26.07
- Revenue Growth
- TACH N/A
- KMDA 11.83
- 52 Week Low
- TACH $9.51
- KMDA $4.74
- 52 Week High
- TACH $10.48
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- TACH N/A
- KMDA 65.83
- Support Level
- TACH N/A
- KMDA $6.78
- Resistance Level
- TACH N/A
- KMDA $7.09
- Average True Range (ATR)
- TACH 0.00
- KMDA 0.16
- MACD
- TACH 0.00
- KMDA 0.04
- Stochastic Oscillator
- TACH 0.00
- KMDA 98.48
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.